Abstract
BACKGROUND: Cysteinyl leukotriene release in association with airway inflammation is a feature of clinical asthma. The acute effects of montelukast (MK-0476), a potent, orally administered, specific cysteinyl leukotriene receptor antagonist, on airways obstruction was assessed in patients with mild to moderately severe asthma. METHODS: Twenty two asthmatic subjects were randomised to receive montelukast, 100 mg or 250 mg, or placebo in a double blind, three period, crossover trial. Ten of the patients were using concomitant inhaled corticosteroids. RESULTS: Montelukast increased the forced expiratory volume in one second (FEV1) from predose baseline values compared with placebo, the percentage point differences between montelukast and placebo being 8.6% (95% CI 3.6 to 13.6) and 8.5% (95% CI 3.5 to 13.5) for the 100 mg and 250 mg doses, respectively. CONCLUSION: Single oral doses of montelukast 100 mg and 250 mg produced significant increases in FEV1 irrespective of the concurrent use of inhaled corticosteroids in asthmatic subjects with airflow limitation.
Full Text
The Full Text of this article is available as a PDF (103.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cloud M. L., Enas G. C., Kemp J., Platts-Mills T., Altman L. C., Townley R., Tinkelman D., King T., Jr, Middleton E., Sheffer A. L. A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am Rev Respir Dis. 1989 Nov;140(5):1336–1339. doi: 10.1164/ajrccm/140.5.1336. [DOI] [PubMed] [Google Scholar]
- Dworski R., Fitzgerald G. A., Oates J. A., Sheller J. R. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med. 1994 Apr;149(4 Pt 1):953–959. doi: 10.1164/ajrccm.149.4.8143061. [DOI] [PubMed] [Google Scholar]
- Gaddy J. N., Margolskee D. J., Bush R. K., Williams V. C., Busse W. W. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis. 1992 Aug;146(2):358–363. doi: 10.1164/ajrccm/146.2.358. [DOI] [PubMed] [Google Scholar]
- Hong S. L., Levine L. Inhibition of arachidonic acid release from cells as the biochemical action of anti-inflammatory corticosteroids. Proc Natl Acad Sci U S A. 1976 May;73(5):1730–1734. doi: 10.1073/pnas.73.5.1730. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hui K. P., Barnes N. C. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet. 1991 May 4;337(8749):1062–1063. doi: 10.1016/0140-6736(91)91709-4. [DOI] [PubMed] [Google Scholar]
- Impens N., Reiss T. F., Teahan J. A., Desmet M., Rossing T. H., Shingo S., Zhang J., Schandevyl W., Verbesselt R., Dupont A. G. Acute bronchodilation with an intravenously administered leukotriene D4 antagonist, MK-679. Am Rev Respir Dis. 1993 Jun;147(6 Pt 1):1442–1446. doi: 10.1164/ajrccm/147.6_Pt_1.1442. [DOI] [PubMed] [Google Scholar]
- Jones T. R., Labelle M., Belley M., Champion E., Charette L., Evans J., Ford-Hutchinson A. W., Gauthier J. Y., Lord A., Masson P. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol. 1995 Feb;73(2):191–201. doi: 10.1139/y95-028. [DOI] [PubMed] [Google Scholar]
- Manning P. J., Watson R. M., Margolskee D. J., Williams V. C., Schwartz J. I., O'Byrne P. M. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med. 1990 Dec 20;323(25):1736–1739. doi: 10.1056/NEJM199012203232504. [DOI] [PubMed] [Google Scholar]